This educational initiative is targeted to oncology pharmacists and specialty pharmacists practicing in immuno-oncology. Program attendees will gain insights into the molecular heterogeneity and diverse clinical features of TNBC, a condition which comprises 15-20% of all breast cancer cases, and has historically had limited treatment options, been associated with earlier age of onset, more aggressive disease course, and poorer prognosis. Attendees will also review the current state of immunotherapy research in TNBC, including completed and ongoing clinical trials across various stages of the disease continuum, the approval of emerging agents and indications throughout the treatment calculus, and prospective avenues of research focus, such as the identification of predictive novel biomarkers to help guide treatment decisions. Finally, using an interactive, case-based approach, this symposium will comprehensively evaluate current clinical challenges in TNBC management and examine adaptive strategies that oncology pharmacists can employ to optimize patient outcomes in the era of immunotherapy.



Sandra Cuellar, PharmD, BCOP

University of Illinois Hospital & Health Sciences System
Chicago, Illinois
View Full Bio

Rita Nanda, MD

Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, Illinois
View Full Bio



In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-20-007-L01-P).


Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.


Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from Merck & Co., Inc.